Hugh Rogers on the Next Opportunity in Infectious Disease Detection

CSE's Anil Mall was recently joined by Hugh Rogers, CEO of XPhyto Therapeutics Corp. (CSE:XPHY), to discuss how the "science-first" cannabis company prioritizes its focus on formulation, clinical validation, and emerging European markets.

In this discussion, Hugh shares how the company has built a "cultivation independent" operating philosophy that sidesteps the overhead associated with large cultivators (2:29), the newest pillar to their business focused on infectious disease screening (6:00), and the advantages that the company has by sticking firmly to their "science-first" mission (14:41).

Listen until the end to hear Hugh's insights into how he built his team through unique collaborations at the University of Alberta and the Technical University of Munich!